Hormone Receptor-Positive Breast Cancer
Features of HR+ breast cancer
• About 2/3 of breast cancers
• Tends to grow more slowly than other types of breast cancers
• Tends to have a better outcome in the short-term
• Exhibits one or both of estrogen and progesterone receptors
• Growth of cancer cells is fuelled by estrogen and/or progesterone
Who gets HR+ breast cancer ?
• Older women
How to treat metastatic HR+ breast cancer ?
•T
reated with hormone therapies that lower estrogen level (tamoxifen) or block estrogen receptors (the
aromatase inhibitors anastrozole, letrozole or exemestane)
•H
as a slightly lower chance of breast cancer recurrence after treatment
WHEN THE FIRST TREATMENT LINE DOESN’T WORK
The first-line therapy might fail, might help for a while and then stop working, or
might cause severe side effects.
A second round of therapy is needed and the increasing number of additional-line
therapeutic options makes the choice difficult.
WHICH STRATEGY TO ADOPT ?
OncoDNA helps you reach a decision
Integrative molecular profiling of PI3K/AKT/mTOR pathway
Aberrantly activated PI3K/AKT/mTOR confers resistance to hormonal therapies.
Predict potential benefit from everolimus, FDA approved in combination with exemestane.
More than 20 clinical trials are recruiting to test efficiency of single and dual inhibitors of PI3K and mTOR
Integrated assessment of cell-cycle control dysregulation
Predict potential benefit from palbociclib, FDA approved in combination with letrozole.
More than 15 clinical trials are recruiting to test efficiency of CDK4/6 inhibitors
Gain-of-function ESR1 mutations testing
Predict resistance to hormonal therapy
Determination of multidrug resistance (MDR1) expression levels
Predict resistance to chemotherapy
And other molecular tests
To empower your clinical decision-making regarding the wide choice of available treatments
OncoDNA SA | 1 Rue Louis Breguet, 6041 Gosselies - Belgium | www.oncodna.com | [email protected]
INTRODUCTION
HR+ breast Cancer
A 65-year-old post menopausal woman was diagnosed with bilateral infiltrating
lobular carcinoma. She underwent a bilateral mastectomy and histopathology
revealed an ER positive, PR negative and HER2 negative tumor. After surgery, she
received several lines of chemotherapeutic regimen including taxane, 5-FU and
anastrozole. Six months later, PET scan revealed bone metastases. Oncologist used
OncoSTRAT&GO to discover potentially beneficial treatment options.
CONCLUSION
OncoSTRAT&GO solution
The oncologist has decided to start everolimus therapy. Follow up PETscan showed a reduction in bone metastases.